A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) posttransplant. Following melphalan (200 mg/m 2 ) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m 2 /day) began on day 5. Fifteen of 19 patients completed therapy. No treatment-related deaths occurred. IL-2 (1 Â 10 6 IU/m 2 / day) was not tolerated in two of six patients due to Xgrade 3 fatigue/diarrhea (n ¼ 1) or supraventricular tachycardia (n ¼ 1). The maximum tolerated dose of IL-2 was 6 Â 10 5 IU/m 2 /day; this dose was well tolerated by 11 of 13 patients. Neutrophil and platelet engraftment occurred on day 13 (median; range 10-17 days) and day 13 (median; range 0-74 days), respectively. When compared to control patients, there was a marked increase in the number of CD3 þ T cells (P ¼ 0.005), CD4 þ T cells (P ¼ 0.01), CD8 þ T cells (P ¼ 0.001) and CD4 þ CD25 þ Treg cells (P ¼ 0.015) post-transplant. Cytotoxicity directed against myeloma cells was markedly increased when compared to control patients (P ¼ 0.017). This unique trial design using early administration of IL-2 with GM-CSF during the period of lymphodepletion, demonstrated a marked increase in the number and function of early cytotoxic effector T cells, without suppression of engraftment.
Introduction
Although autologous stem cell transplant improves survival in patients with myeloma, the majority of patients relapse.
1,2 The high relapse rate following autologous transplant and the limited availability of an allogeneic donor stresses the critical need for innovative therapies. Post-transplant immunotherapy provides a non-cross resistant mechanism of tumor cell killing, in a setting of minimal residual disease. Following myelosuppressive therapy, depletion of T suppressor cells with reconstitution of cytotoxic lymphocytes occurs. As a result, tumors may regress due to an immune environment conducive to killing malignant cells. [3] [4] [5] The importance of lymphocyte recovery is demonstrated by the improved survival in patients with a hematologic malignancy who demonstrate an early lymphocyte recovery post-transplant. [6] [7] [8] Data to date demonstrate the importance of the absolute lymphocyte count at day 15 following transplantation, suggesting that various T-cell populations may be contributing to this effect, including CD56 þ natural killer (NK) cells, CD4 þ T cells or CD8 þ T cells. Preclinical data using human expanded T-cell populations demonstrate the in vitro killing of myeloma cells, emphasizing the critical role that T cells, and T-cell subsets, play in killing tumor cells. [9] [10] [11] [12] [13] We postulate that therapies that rapidly increase lymphocyte numbers following transplant will enhance immune reconstitution and improve outcomes.
Based on our previous pre-clinical data and clinical trials, a Phase I/II clinical trial was designed to identify the maximum tolerated dose (MTD) of early administration and dose escalation of post-transplant interleukin (IL)-2 in patients with multiple myeloma receiving high-dose melphalan, followed by autologous peripheral blood stem cell transplantation. [14] [15] [16] [17] [18] The uniqueness of this trial is the early administration of IL-2 on the day of transplant, during the period of lymphodepletion, demonstrating potentially beneficial immune recovery without suppression of engraftment. This is the first clinical trial that we are aware of using IL-2 and granulocyte macrophage colony stimulating factor (GM-CSF) in combination post-transplant. The post-transplant immunotherapy consisted of the combina-tion of GM-CSF and IL-2, with IL-2 beginning on the day of transplant and continuing for 4 weeks. GM-CSF was started on day 5 following transplant and continued until engraftment. We describe the laboratory data and the clinical results from this trial. Improved immune recovery within 4 weeks was demonstrated by a marked increase in the number of CD3 þ T cells, CD4 þ T cells and CD8 þ T cells and an increase in cytotoxicity directed against human myeloma cells. This clinical trial model provides an attractive addition to high-dose chemotherapy and autologous stem cell transplantation for patients with multiple myeloma. These results currently serve as the platform for additional novel trials at our institution, with the addition of tumor-specific immunotherapy. In addition, current research is elucidating the mechanism(s) of tumor cell killing in vivo, using this model.
Materials and methods

Patient population and eligibility criteria
Patients were required to have pathologically confirmed multiple myeloma with therapy-sensitive disease, that was either recently diagnosed, or progressive/relapsed disease following initial remission. Patients between the ages of 17 to 70 years, with a Karnofsky status of X80% were eligible. Adequate cardiopulmonary function was required, including a systolic cardiac ejection fraction X45%, DLCO X60%, FEV1 and FVC both X70% of predicted. Creatinine was required to be o3.0 with a measured creatinine clearance 450 ml/min. The patients needed adequate bone marrow function, unless due to the underlying myeloma. The protocol was approved by Dartmouth Medical School's Committee for the Protection of Human Subjects. All patients signed an informed consent.
Control cohort
While the trial was ongoing, eight patients with myeloma received an autologous stem cell transplant using high-dose melphalan and either G-CSF or GM-CSF post-transplant. This group of eight patients signed an informed consent allowing us to obtain blood samples from them for laboratory analyses. This group of eight patients served as the 'control cohort' for the laboratory analyses.
Treatment plan
Mobilization. Before transplantation, each patient received chemotherapy (or the equivalent) with evidence of responsive disease. Peripheral blood stem cells were mobilized using cyclophosphamide (3-5 g/m 2 ) with recombinant G-CSF (Amgen, Thousand Oaks, CA, USA) (10 mcg/kg/day) or recombinant G-CSF (10 mcg/kg/day) alone. Following cyclophosphamide mobilization, leukapheresis was initiated after recovery of the WBC count to 1000 cells/ml or greater. In addition, the peripheral blood CD34 cell number was required to be X5 CD34 þ cells/ml. For patients receiving cytokine mobilization, leukapheresis was initiated on the 5th day following the start of G-CSF. Daily leukaphereses of approximately 15-20 l of whole blood (approximately 3.5-4.5 total blood volumes over the course of 300 min) were performed and continued until more than 3 Â 10 6 CD34 þ cells/kg had been collected. ) was administered on day À3. With the initiation of the melphalan, prophylactic medications were administered, including ciprofloxacin, penicillin, acyclovir and fluconazole. Hematopoietic progenitor cells were re-infused on day 0, 48-72 h following the administration of melphalan.
The design of the clinical trial, including dose escalation and duration of IL-2 (Chiron, Emeryville, CA, USA) therapy, was based on previous results.
14-18 IL-2 began on day 0, the day of the stem cell infusion. IL-2 was administered as twice-a-day subcutaneous injections, and given on a 5 days on/2 days off cycle, for 4 consecutive weeks. IL-2 dose escalation is described in , respectively. The number of platelet units or red blood cell units administered was recorded from the day of admission until discharge.
Engraftment was defined as an absolute neutrophil count of X500 cells/mm 3 for 3 days and a platelet count of X20 000 cells/mm 3 for 3 days (untransfused). The first of the 3 days was defined as the engraftment day, respectively.
Monitoring after discharge. Following discharge, patients were evaluated weekly in the outpatient transplant clinic for one month and then returned to their referring Definitions of response. Complete response required the disappearance of monoclonal protein in serum and urine on immunofixation analysis, and attainment of a bone marrow biopsy with less than 5% plasma cells. Skeletal X-rays were required to show either recalcification or no change in lytic lesions. Partial response was defined as greater than 50% reduction in monoclonal protein in serum and urine, a decrease in bone marrow plasma cells by at least 25%, and no increase in size or number of lytic lesions. Mixed response showed clinical and radiographic evidence of improvement with areas of progression.
A patient was defined as having progressive disease if one of the following criteria was met: (1) an increase of X25% in either urine or serum monoclonal protein, (2) an increase of X25% in the size of a preexisting lytic lesion, (3) a new lytic lesion or (4) an increase of X25% plasma cells in the bone marrow. All patients not meeting one of the above categories were defined as having stable disease.
The survival of patients and duration of response were measured from the date of transplant.
Laboratory analysis
Phenotypic analyses of peripheral blood mononuclear cells. Blood samples were obtained from each patient, before transplant (baseline), and then weekly post-transplant until week 4. Phenotypic analyses of patient's peripheral blood mononuclear cells (PBMNC) at day 21 post-transplant were compared to values obtained from the control group. Following Ficoll-Hypaque separation, mononuclear cells from each blood sample were incubated with antibodies for 60 min at 41C. After washing three times with cold phosphate-buffered saline, cells were fixed with 0.5% paraformaldehyde (Sigma, St Louis, MO, USA). Monoclonal antibodies were used directed against CD3, CD4, CD8, CD56, CD28, CD25, CD45RA, CD45RO conjugated with fluorescein isothiocyanate, phycoerythirin (PE), or PETexas Red (ECD) (Beckman Coulter, Fullerton, CA, USA). Cells were analyzed using standard three-color flow cytometry (FACscan, Becton, Dickinson, San Jose, CA, USA).
Tumor cell lines. Two human myeloma cell lines, RPMI 8226 and U266, were obtained from American Type Culture Collection (Rockville, MD, USA). Cell lines were cultured in RPMI 1640 (Cellgro, Herndon, VA, USA) containing 10% fetal bovine serum (FBS, Life Technologies, Rockville, MD), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen Corp., Carlsbad, CA, USA).
Cytotoxicity of patients' blood mononuclear cells posttransplant. Cytotoxicity of patient's PBMNC at day 21 post-transplant were compared to samples from the control group. Cryopreserved PBMNC were thawed rapidly in 371C water bath and washed twice with AIM-V medium (Life Technologies, Rockville, MD, USA). Following determination of viability using Trypan Blue, 1 Â 10 6 cells/ ml cells were placed in T-75 cm 2 tissue culture flasks (Costar, Cambridge, MA, USA) in serum-free AIM-V medium, supplemented with 1000 IU/ml IL-2 (Chiron, CA, USA) and incubated in 5% CO 2 at 371C for 24 h. An additional 5000 IU/ml of IL-2 was added on day 2. PBMNC from the control patients were treated in the same manner (as outlined above) and served as the controls. After 48 h of incubation, cells were harvested, washed twice with AIM-V medium, and used as the effector cells in standard 4-h 51 Cr-release assay. Two human myeloma cell lines, RPMI 8226 and U266, were used as target cells. Each experiment was performed using triplicate samples. The percentage lysis was calculated using a standard formula.
Statistical methods
The clinical trial was designed to establish the MTD of IL-2 in myeloma patients conditioned with high-dose melphalan and receiving GM-CSF post-transplant. Using a modified Fibronacci escalation scheme, cohorts of three or six patients were treated at each dose level, beginning with IL-2 dose level 0 (6 Â 10 5 IU/m 2 /day). If no grade III-IV toxicities were observed at that dose level, subsequent patients were entered into higher dose levels. The MTD was defined as the highest dose level at which fewer than 33% of patients experienced a dose-limiting toxicity (DLT), defined as grade III or IV toxicities. Beginning with dose level 0, three patients were initially treated at each dose level. If DLT was observed in one of these three patients, the cohort was expanded to a total of six patients at that dose level. Dose escalation occurred if DLT was observed in none of three, or one of six patients. Otherwise, if, at any time, DLT was observed in at least two patients in a given cohort, accrual of patients to that cohort was stopped. The MTD would be declared as the next lower dose level. In the event that a patient was not evaluable for toxicity, that patient was replaced by enrolling another patient at the current dose level. Any patient experiencing any DLT would be considered evaluable for toxicity.
When analyzing the results of the flow cytometry and cytotoxicity data using patient samples (study patients versus control patients), the differences were compared using Student's t-test.
Results
Patient demographics and disease characteristics
Nineteen myeloma patients were treated (Stage I n ¼ 1, Stage II n ¼ 8, Stage III n ¼ 10; Durie Salmon). Twelve patients were female, and the median age was 57 years (range 46-70) (Tables 2 and 3 ). At the time of transplant, all patients demonstrated treatment-sensitive disease and were in partial remission.
Engraftment, blood product support and length of stay Following transplantation, all patients engrafted. The number of days required for the ANC to reach 500 cells/ mm 3 was 13 days (median; range 10-17 days). The number of days required for the platelet count to reach 20 000 cells/ mm 3 was 13 days (median; range 0-74 days). The median number of red blood cell units transfused to each patient was 3 (range 0-10 U). The median number of SDP transfusions required per patient was 2 (range 0-14 U). The length of hospital stay was 21.3 days (median; range 16-42 days).
MTD of post-transplant IL-2
There were no treatment-related mortalities. Non-hematopoietic toxicities (grade III or greater) observed during the transplant course are listed in Table 4 . Treatment with IL-2 began at dose level 0 (6 Â 10 5 IU/m 2 /day) and the initial three patients tolerated therapy without experiencing a DLT. On dose level 1 (1 Â 10 6 IU/m 2 /day), two of six patients experienced a DLT and IL-2 had to be discontinued (Table 5) (Table 5) , presenting as atrial fibrillation and required cardioversion, since the atrial fibrillation was associated with hypotension (Grade IV). Two patients were removed from dose level 0 of IL-2. One patient developed transient supraventricular tachycardia (SVT) (Grade III) that was managed using a combination of medications, including a beta blocker and a calcium channel blocker. The SVT resolved within 3 days of therapy. Another patient was discharged to home and continued to receive IL-2 (dose level 0). She was admitted to another hospital within 3 days following discharge, owing to severe depression (Grade IV) and the IL-2 was discontinued. IL-2 was held for 4 days for one patient (dose No. of pre-transplant therapies level 0) due to fluid retention, vascular leak (Grade IV) and transient SVT (Grade III), responding appropriately to diuresis. IL-2 was restarted in this patient and a full course of IL-2 therapy was successfully completed.
Recovery of cytotoxic effector cells in the peripheral blood post-transplant
Phenotypic analyses of patients' PBMNC at day 21 posttransplant were compared to samples from the control group and demonstrated a marked increase in the number of CD3 þ T cells, in the study cohort (P ¼ 0.005). When compared with results from the control group, the increase in the number of CD4 þ T cells and CD8 þ T cells in the study group was statistically significant (P ¼ 0.01 and P ¼ 0.001, respectively). Although the number of CD8 þ CD56 þ NKT cells increased in both groups, the difference between the two groups was borderline (P ¼ 0.05). There was no difference in the increase in the number of CD56 þ NK cells between the two groups (P ¼ 0.095). The expression of CD25, the IL-2 receptor, was markedly increased in the study group, when compared to the control group (P ¼ 0.025) (Figure 1 ). The number of cells expressing CD4 þ CD25 þ , thought to be T regulatory cells, increased markedly when compared to the number of cells from the control patients (P ¼ 0.015). CD8 þ CD28À T suppressor cells demonstrated no difference between the two groups (P ¼ 0.4) (Figure 2 ). When subpopulations of CD4 þ T memory cells were evaluated, there was a decrease in the number of CD4 þ CD45 þ RA naive T cells in both the study and the control groups (P ¼ 0.06). There was a significant increase in the number of CD4 þ CD45 þ RO memory T cells in the study group, when compared to the number of these cells within the control group (P ¼ 0.03) (Figure 3) .
Cytotoxicity of PBMC post-transplant
Cytotoxicity of the PBMNC from study patients on day 21 post-transplant was strikingly increased when compared to the cytotoxicity results from the control group (P ¼ 0.017 at ET of 100:1) when tested against a human myeloma cell line (RPMI 8226) (Figure 4) . Similar results were obtained for the second cell line U266 (data not shown).
Outcome data
Time to progression, relapse and survival were calculated from the day of transplantation. All patients maintained a partial remission at day 100. No complete remissions were achieved. Follow-up ranged from 5 to 53 months. With a median follow-up duration of 111 weeks (range 19-203 weeks), 14 patients are alive, with 12 patients demonstrating slowly progressive disease. The average time to progression was 81 weeks. Four patients died due to progressive disease. One patient died of unrelated causes and was in PR at the time of death. Two patients remain alive in PR without evidence of progressive disease (Table 3) .
Discussion
This Phase I-II clinical trial, utilizing the combination of early administration of post-transplant IL-2 and GM-CSF, 
Toxicities were graded according to NCI Common Toxicity Criteria (version 3.0); ''n'' is the number of patients experiencing the toxicity. One patient could experience one or more toxicities. demonstrated a well-tolerated regimen that can be safely administered immediately following transplant, without a delay in engraftment. It should be noted that patients participating in this study were favorable since they were required to have treatment-sensitive disease going into transplant. The maximum tolerated subcutaneous dose of IL-2 was 6 Â 10 5 IU/m 2 /day administered for 5 of 7 days each week for 4 weeks. At this dose level, 11 of 13 patients completed the full course of therapy. Corresponding laboratory results demonstrate enhanced immune recovery post-transplant, as indicated by the increased effector cell number and function of the cytotoxic T cells. The number of CD3 þ T cells, CD4 þ T cells, CD8 þ T cells increased significantly within 4 weeks following transplant when compared to results from control patients. Myelomadirected cytotoxicity using patient's PBMNC also strikingly increased, when compared to control patients.
Emerging data stress the importance of the recovering immune system following transplantation. Improved survival is observed in patients with a hematologic malignancy experiencing an early lymphocyte recovery following transplant. [6] [7] [8] In addition, an increased number of lymphocytes within the infused stem cell product correlates with improved outcome in myeloma patients. 19 A large Eastern Cooperative Oncology Group trial demonstrated the importance of an increased number of CD4 þ T cells at various time points following transplantation. Higher peripheral blood T-cell numbers, up to 2 years following transplant, correlated with improved survival. 20 An early increase in the number of CD8 þ T cells following transplant is critical, since these cells may generate a graft-versus-tumor effect. 21 Although the absolute lymphocyte count on day 15 following transplant correlates with an improved overall and disease-free survival, the exact mechanism is uncertain. Recovering lymphocytes may originate from the infused graft, originate from the recipient and survive the induction therapy, or mature from early CD34 þ stem cells, either from the graft or the recipient. Data suggest critical roles for CD56 þ NK cells or CD4 þ T cells within the autologous graft, or circulating CD8 þ T cells immediately following the transplant. [22] [23] [24] A number of variables may affect immune reconstitution and lymphocyte recovery. Some of these variables include the type and number of pre-transplant therapies, the number of cells infused, and time from diagnosis until transplant. Although these variables were evaluated, the number of patients within our cohort was too small to identify statistically significant patterns or responses.
Our results indicate the recovery of a large number of CD4 þ CD25 þ T cells, either T regulatory cells or activated T cells, with low numbers of T suppressor cells (CD8 þ CD28À) immediately following transplant. In the non-transplant setting, both lymphopenia and the administration of IL-2 aggressively stimulate T regulatory cell recovery. 25, 26 A similar scenario is likely occurring in these transplant patients. Recent evidence demonstrates that recombinant IL-2 will induce expansion of Tregs in vivo, through a STAT-dependent mechanism. 27 Additional laboratory studies are underway attempting to differentiate the recovering CD4 þ CD25 þ cells as T regulatory or activated T cells.
Following high-dose chemotherapy, lymphodepletion occurs during the period of pancytopenia. 3, 4, 25, 26 This lymphodepletion results in decreased numbers of suppressive cells (CD8 þ CD28À T suppressors) and creates an optimal period for manipulation of immune recovery. Following lymphodepletion, the lymphocyte compartment re-populates in an orderly fashion, providing a 'window' when tolerogenic lymphocytes are absent. 3, 4, 28 Radiationinduced lymphodepletion in tumor-bearing mice leads to complete remissions. 29 Lymphodepletion with adoptive cellular therapy boosts anti-tumor immunity in animals and in humans. 5 Chemotherapy-induced lymphodepletion followed by infusion of ex vivo expanded tumor-specific lymphocytes with IL-2 and GM-CSF has been used in melanoma patients. 3, 4, 30 These clinical studies demonstrate that lymphodepletion exhausts regulatory cells, with subsequent diminution of the host de novo tolerogenic environment, allowing for tumor-directed CTL expansion with improved anti-tumor activity. These recent results support the hypothesis that lymphodepletion, followed by cytokine therapy with GM-CSF (which restores antigen presenting cells) and IL-2 (an activating CTL cytokine) may convert naive T cells to tumor-specific CTLs and expand existing tumor-specific CTL precursors. 3, 4, 29 Effector function of the restored memory T cells requires antigen stimulation, which may be provided by GM-CSF expansion of antigen presenting cells. We hypothesize that lymphodepletion not only creates room for expansion of cancer-specific CTLs, but also with the administration of IL-2, activates stimulatory signals of immune recovery.
The uniqueness of this trial design is the early administration of IL-2 on the day of transplant, during the period of lymphodepletion, demonstrating potentially beneficial immune recovery, without suppression of engraftment. The administration of post-transplant IL-2 has been evaluated in various malignancies, sometimes in combination with other cytokines or with adoptive cellular therapies. [31] [32] [33] [34] [35] [36] The majority of these trials initiate IL-2 months following transplant, due to the potential for marrow suppression and the toxicities associated with IL-2. Our preliminary mouse models and early clinical trials, along with the recent publications focusing on the concept of lymphodepletion, emphasize the critical need to initiate IL-2 early posttransplant, in order to influence immune recovery during this period of immune recovery. [14] [15] [16] [17] [18] The results of this trial emphasize the narrow therapeutic dose of post-transplant IL-2. Despite the low dose of IL-2 in this trial, when used in combination with GM-CSF, immune reconstitution is clearly affected by this regimen. An additional uniqueness of this trial is that GM-CSF, rather than G-CSF was selected, due to its potential immunomodulatory effects. In particular, GM-CSF demonstrates a propensity to improve presentation of antigen and enhanced monocyte/macrophage function. [37] [38] [39] [40] This is the first clinical trial, that we are aware of, using these two medications in combination posttransplant.
These results demonstrate an immunotherapy regimen that influences immune recovery post-transplant, as demonstrated by intriguing laboratory results. The enhanced cytotoxic function of the recovering lymphocytes may eradicate minimal residual disease, and therefore, may improve outcomes. Further trials at our center are carried out attempting to elucidate the mechanisms of tumor cell killing using cytokine immunotherapy, in combination with adoptive cellular therapy. This clinical 'model' can easily be adapted to other hematologic malignancies. We are hopeful that the enhanced immune recovery may translate into an improved clinical outcome.
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